Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: the upside continues

August 29, 2018 5:54pm

Volume is still low with a few big moves to the upside but, generally it’s not an “earth shaking” session

I’m still nervous after the spike of another high as a long holiday weekend looms

Pre-open indications: 2 HITs and 0 MISS

Presenting alternative hypotheses clarifies material facts and evidence available to investors. “Devil’s Advocacy” also provides greater confidence that the current sector outlook will hold-up to close scrutiny!

When is it wrong to be early in sector prognosis? Your portfolio should be profiting from RMi’s analysis!

Henry’omics:

Investors are about to step into September, after August has delivered some good gains - more trade deadlines, a potential U.S. government shutdown and another Fed meeting, for starters — that should keep investors nervous.

Remember September has historically been a pretty tough month for equities and it’s also the end of Q3.

Investor sentiment was boosted today by the resumption of U.S. - Canada trade talks.

I’m still sticking with my SELL warning – every time I see or hear about a new high – I say – BYE!

… By lightening the “load”!

Pre-open indications: 2 HITs and 0 MISS

Mesoblast (MESO) closed up +$0.09 – hit;
Ultragenyx (RARE) closed up +$5.36 – hit;

From the pre-open newsletter: “Getting an itchy trading finger as the month ends? August is coming to an end (2 days) after 18 sessions – 5 had negative and 13 had positive closes; in the past 5 sessions – 4 closed positive with 1 negative close and of the past 10 sessions – 2 had closed negative.”

Of the 45 companies covered on Wednesday; 9 downside equities finished in a range of -0.20% (CLLS) to -3.13% (AST) while the 33 upside equities oscillated from +0.13% (FIXX) to +21.31% (KOOL +0.07) with 3 flat closes (RENE.L, PSTI and ADRO).

Daily analytics and metrics:

The Dow closed up +61.29 points or +0.24% to 26.125.31
The S&P closed up +16.55 points or +0.57% to 2,914.04
The NASDAQ closed up +79.65 or +0.99% to 8,109.69

The advance/decline line scenario of 45 covered companies:

The open was positive with an A/DL of 23/17 and 5 flats;
The mid-day continued positive with an A/DL of 25/20 and 0 flat;
The close was positive with an A/DL of 33/9 and 3 flats;

The five (5) largest trend lines:

… The greatest volume to the downside: GBT, RGNX, BLCM, BLFS and CLLS

… Upside volume was weighted to: MDXG, KOOL, SGMO, IONS and VSTM

… Leadership ($) to the downside: GBT (-$1.50), RGNX (-$0.40), BLFS (-$0.33), SLDB (-$0.15) and BLCM (-$0.11)

… Best moves ($) to the upside: RARE (+$5.25), SAGE (+$4.71), BKUE (+$2.65), ALNY (+$1.55) and BMRN (+$1.04)

The iShares NASDAQ Biotechnology (IBB) closed:

Wednesday was +1.3%
Tuesday was up +0.49%
Monday was up +1.75%;
Friday was up +0.17 %
Thursday was down -0.58%
Last Wednesday was up +0.71%

August sessions:

Wednesday closed POSITIVE with 9 decliners, 33 advancers and 3 flats;

Tuesday closed POSITIVE with 15 decliners, 28 advancers and 2 flats;

Monday closed POSITIVE with 7 decliners, 35 advancers and 3 flats;

Friday closed POSITIVE with 19 decliners, 24 advancers and 2 flats;

Thursday closed NEGATIVE with 26 decliners, 16 advancers and 3 flats;

Wednesday closed POSITIVE with 12 decliners, 32 advancers and 1 flat;

Tuesday closed POSITIVE with 9 decliners, 36 advancers and 0 flat;

Monday closed POSITIVE with 16 decliners, 23 advancers and 6 flat;

Friday closed POSITIVE with 18 decliners, 24 advancers and 3 flat;

Thursday closed POSITIVE with 16 decliners, 27 advancers and 2 flat;

Wednesday closed NEGATIVE with 36 decliners, 6 advancers and 3 flat;

Tuesday closed POSITIVE with 13 decliners, 28 advancers and 4 flat;

Monday closed NEGATIVE with 24 decliners, 19 advancers and 2 flat;

Friday closed POSITIVE with 19 decliners, 24 advancers and 2 flat;

Thursday closed POSITIVE with 14 decliners, 29 advancers and 2 flat;

Wednesday closed NEGATIVE with 25 decliners, 16 advancers and 4 flat;

Tuesday closed POSITIVE with 14 decliners, 29 advancers and 2 flat;

Monday closed POSITIVE with 19 decliners, 24 advancers and 2 flat;

Friday closed NEGATIVE with 37 decliners, 4 advancers and 4 flat;

Thursday closed POSITIVE with 16 decliners, 27 advancers and 2 flat;

Wednesday (8/1) closed NEGATIVE with 23 decliners, 21 advancers and 1 flat;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.